CAUTION: Federal law (USA) restricts this device to sale by or on the order of a licensed practitioner.
Prior to use, please refer to all applicable “Instructions for Use” for more information on Intended Use/Indications for Use, Contraindications, Warnings, Precautions, Potential Adverse Events, and Operator’s Instructions.
INTENDED USE/INDICATIONS FOR USE
The WATCHMAN FLX Device is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who:
- Are at increased risk for stroke and systemic embolism based on CHA2DS2-VASc scores and are recommended for anticoagulation therapy;
- Are deemed by their physicians to be suitable for anticoagulation therapy; and
- Have an appropriate rationale to seek a non-pharmacologic alternative to anticoagulation therapy, taking into account the safety and effectiveness of the device compared to anticoagulation therapy.
CONTRAINDICATIONS
Do not use the WATCHMAN FLX Device if:
- Intracardiac thrombus is present.
- An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present.
- The LAA anatomy will not accommodate a Closure Device (see Table 62).
- The patient has a known hypersensitivity to any portion of the device material or the individual components (see Device Description section) such that the use of the WATCHMAN FLX Device is contraindicated.
- Any of the customary contraindications for other percutaneous catheterization procedure (e.g., patient size too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present.
- There are contraindications to the use of anticoagulation therapy, aspirin, or P2Y12 inhibitor.
WARNINGS
Implantation of the WATCHMAN FLX Device should only be performed by interventional cardiologists and/or electrophysiologists who are proficient in percutaneous procedures, transseptal procedures, the imaging modality utilized and who have completed the WATCHMAN FLX Physician Training program.
- For single use only. Do not reuse, reprocess, or resterilize. Reuse, reprocessing, or resterilization may compromise the structural integrity of the Closure Device and/or lead to Closure Device failure which, in turn, may result in patient injury, illness, or death. Reuse, reprocessing, or resterilization may also create a risk of contamination of the Closure Device and/or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the Closure Device may lead to injury, illness, or death of the patient.
- This device has not been studied in pregnant or breastfeeding women. Careful consideration should be given to use of the Closure Device in pregnant and/ or breastfeeding women due to the risk of significant exposure to x-rays and the use of anticoagulation medication.
- Device selection should be based on accurate LAA measurements obtained using transesophageal or intracardiac echocardiographic imaging guidance in multiple views to avoid improper Closure Device sizing. For TEE recommended in multiple angles [e.g., 0°, 45°, 90°, 135°]; For ICE imaging, visualization of the LAA is recommended with the following anatomical structures: aortic valve (short-axis), mitral valve (long-axis), and pulmonary artery (short-axis), to assess the minimum and maximum diameter of the LAA ostium.
- Do not release (i.e., unscrew) the WATCHMAN FLX Device from the core wire unless all release criteria (Step 15) are satisfied to avoid suboptimal results.
- Potential for Closure Device embolization exists with cardioversion < 30 days following Closure Device implantation; verify Closure Device position after cardioversion during this period.
- If thrombus is observed on the device, anticoagulation therapy is recommended until resolution of thrombus is demonstrated by TEE.
- Appropriate post-procedure drug therapy should be followed. See Post-Procedure Information section for further detail.
- Do not use if the temperature exposure indicator dot is red or missing, indicating Closure Device performance may have been compromised.
PRECAUTIONS
- The safety and effectiveness (and benefit-risk profile) of the WATCHMAN FLX Device has not been established in patients for whom long-term anticoagulation is determined to be contraindicated.
- The LAA is a thin-walled structure. Use caution when accessing the LAA and deploying, recapturing, and repositioning the Closure Device.
- Use caution when introducing a WATCHMAN Access System to prevent damage to cardiac structures.
- Use caution when introducing the Delivery System to prevent damage to cardiac structures.
- To prevent damage to the Delivery Catheter or Closure Device, do not allow the WATCHMAN FLX Device to protrude beyond the distal tip of the Delivery Catheter when inserting the Delivery System into the Access Sheath.
- If using a power injector, the maximum pressure should not exceed 690 kPa (100 psi).
- Use caution when manipulating the Delivery System. Excessive counterclockwise rotation of the deployment knob or Delivery System hub independent from the rest of the Delivery System can cause premature implant detachment.
MRI SAFETY INFORMATION
A person with the Boston Scientific WATCHMAN FLX Pro Closure Device may be safely scanned under the following conditions. Failure to follow these conditions may result in injury.
Device Name | WATCHMAN FLX Pro Closure Device |
---|---|
Static Magnetic Field Strength (Bo) | 1.5 T or 3.0 T |
Maximum Spatial Field Gradient | 40 T/m (4,000 gauss/cm) |
RF Excitation | Circularly Polarized (CP) |
RF Transmit Coil Type | There are no Transmit Coil restrictions |
RF Receive Coil Type | Any |
Operating Mode | Normal Operating Mode |
Maximum Whole-Body SAR | 2 W/kg (Normal Operating Mode) |
Maximum Head SAR | 3.2 W/kg (Normal Operating Mode) |
Scan Duration | 2 W/kg whole-body average SAR for 60 minutes of continuous RF (a sequence or back-to-back series/scan without breaks) |
MR Image Artifact | The presence of this implant may produce an image artifact of up to 8 mm. |
If information about a specific parameter is not included, there are no conditions associated with that parameter.
POTENTIAL ADVERSE EVENTS
Potential adverse events (in alphabetical order) which may be associated with the use of a left atrial appendage closure device or implantation procedure include but are not limited to:
- Air embolism
- Airway trauma
- Allergic reaction to the contrast media, anesthetic, WATCHMAN Implant material, or medication
- Altered mental status
- Anemia requiring transfusion
- Anesthesia risks
- Angina
- Anoxic encephalopathy
- Arrhythmias
- Atrial septal defect
- Bruising, hematoma, or seroma near the catheter insertion site
- Cardiac perforation
- Chest pain/discomfort
- Confusion post procedure
- Congestive heart failure
- Contrast related nephropathy
- Cranial bleed
- Death
- Decreased hemoglobin
- Deep vein thrombosis
- Device embolism
- Device fracture
- Device thrombosis
- Edema
- Embolism
- Excessive bleeding
- Fever
- Fistula
- Groin pain
- Groin puncture bleed
- Hematuria
- Hemoptysis
- Hypotension
- Hypoxia
- Improper wound healing
- Inability to reposition, recapture, or retrieve the device
- Infection/pneumonia
- Interatrial septum thrombus
- Intratracheal bleeding
- Major bleeding requiring transfusion
- Misplacement of the device/improper seal of the appendage/movement of device from appendage wall
- Myocardial erosion
- Myocardial infarction
- Nausea
- Oral bleeding
- Pericardial effusion/tamponade
- Pleural effusion
- Prolonged bleeding from a laceration
- Pseudoaneurysm
- Pulmonary edema
- Radiation injury
- Renal failure
- Respiratory insufficiency/failure
- Stroke - Hemorrhagic
- Stroke - Ischemic
- Surgical removal of the device
- TEE complications (e.g., throat pain, bleeding, esophageal trauma)
- Thrombocytopenia
- Thrombosis
- Transient ischemic attack (TIA)
- Valvular or vascular damage
- Vasovagal reactions
There may be other potential adverse events that are unforeseen at this time.
92574167 B.5